Ollo Roland Somé^1,*, Abdoul Halim Bagué², Damien Konkobo¹, Dieudonné Hien³, Adama Dembélé³, GL Hermann Bélemlilga¹, Valentin Konségré⁴, Nayi Zongo⁵

Oncologie, Vol.24, No.2, pp. 173-184, 2022, DOI:10.32604/oncologie.2022.021250

Abstract Introduction: Breast cancer management in Sub-Saharian Africa, is faced with diagnosis and treatment challenges. This study aims to describe, breast cancers epidemiology in Bobo-Dioulasso, Burkina Faso. Patients and method: A retrospective cohort study was performed from July 01, 2015 to December 31, 2021 in the Souro Sanou university teaching hospital. Histologically confirmed breast cancer patients were included. Clinical aspect, treatment features and outcome data were collected and analyzed. Results: In study time, eight male’s cases (2%) 360 female’s cases among 368 breast cancers cases were included. The mean age was 46.6 ± 12.1 years, ranging from 15 to 90. The… More >

E. du Rouchet, C. Dendoncker

Oncologie, Vol.21, No.2, pp. 125-134, 2019, DOI:10.3166/onco-2019-0042

Abstract For a patient suffering from breast cancer, access to the initial treatment includes several steps like confirmation of an anatomopathological diagnosis, proposition and establishment of an individualized treatment plan, pretreatment assessments, and access to the technical platform. The accumulated duration of these intervals plays a role in the prognosis in the early stages of the disease. In addition, it is important to manage all the uncertainties, both diagnostic and prognostic, which will inevitably upset the patient’s psychological balance. Supported by literature, recommendations and more than 20 years of experience in a multidisciplinary centre, the authors propose the organization of an… More >

V. Allouchery, L. Augusto, F. Clatot

Oncologie, Vol.21, No.1, pp. 40-48, 2019, DOI:10.3166/onco-2019-0035

Abstract It has been known for a long time that circulating tumor cells (CTC) as well as circulating tumor DNA (ctDNA) can be detected. However, only recent technical advances allowed evaluating the interest of CTC and ctDNA in breast cancer. In both early and metastatic breast cancers, CTC detection is a recognized factor for poor outcome. Nevertheless, CTC detection does not impact cancer management yet. The use of ctDNA in daily practice will require validation by prospective data. But ctDNA seems particularly promising both for residual disease evaluation and identification of tumor clones harbouring mutations (PI3KC, ESR1) and may predict efficacy… More >

Delphine Déniel Lagadec^1,2,*, Laurence Guen^1,2, Fabienne Le Goc Le Sager¹, Sandrine Estivin^1,3, Christophe Perrin^1,4

Oncologie, Vol.23, No.1, pp. 39-46, 2021, DOI:10.32604/Oncologie.2021.015985

Abstract Since October 2020, the COVID-19 epidemic has affected the care of patients in the field of oncology/hematology in the public and private establishments. The “Unité de coordination en onco-geriatrie région Bretagne” (coordinating unit in onco-geriatrics of the Brittany region) has wished to have a survey with specialists in cancerology so as to make an inventory of the care given to cancer patients aged over 75 in the region. An inquest was made in the course of October 2020, following the first lock down, with 24 specialists. 67% of them feel they lack in clear orders/institutional prescriptions related with this epidemic.… More >

Sophie Piperno-Neumann^1,*, Pascale Mariani², Vincent Servois³, Gaelle Pierron⁴, Livia LumbrosoRouic⁵, Alexandre Matet^5,6, Manuel Rodrigues¹, Nathalie Cassoux^5,6

Oncologie, Vol.22, No.4, pp. 203-212, 2020, DOI:10.32604/oncologie.2020.014102

Abstract Uveal melanoma is a rare subtype of melanoma, intrinsically different from cutaneous melanoma. Despite optimal therapeutic management allowing local control of the primary ocular tumor, 20 to 50% of patients develop metastases, mainly localized to the liver, with a poor prognosis and a 12-month median survival from the diagnosis of the metastatic disease. There is a lack of effective treatments in the metastatic setting, and dedicated strategies and trials for uveal melanoma patients are needed, based on identification of new targets and specific preclinical findings.


Résumé:
Le mélanome de l’uvée est un cancer rare, en tous points différent du mélanome… More >